BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-3579
Full Text
Open PDFAbstract
Available in full text
Date
February 11, 2020
Authors
Publisher
American Association for Cancer Research (AACR)